# Type I allergic reactions FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-i-allergic-reactions

> 1 upcoming FDA catalyst in type I allergic reactions: Anaphylm™ (dibutepinephrine, AQST) on March 16, 2027 (PDUFA date).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for type I allergic reactions?

1 upcoming FDA catalyst in type I allergic reactions: Anaphylm™ (dibutepinephrine, AQST) on March 16, 2027 (PDUFA date). Press release filed with the SEC (EX-99): "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" [Calendar and source filings](https://sec-api.dev/indications/type-i-allergic-reactions)

Source: Press release filed with the SEC (EX-99), accession 0001398733-26-000077, https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/indications/type-i-allergic-reactions#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2024 | [ARS Pharmaceuticals, Inc. NDA/BLA submission](https://sec-api.dev/companies/spry/catalysts) | SPRY | Type I allergic reactions | completed | "In September 2024, ARS Pharma submitted a supplemental New Drug Application (sNDA) for neffy 1 mg for the treatment of Type I allergic reactions, including anaphylaxis, in adults and children who weigh 15 to 30 kg (33-66 lbs.)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-ex99_1.htm)) |
| February 2, 2026 | [Anaphylm™ (dibutepinephrine) complete response letter (CRL)](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed, complete response letter | "On February 2, 2026, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026, for the New Drug Application (NDA) seeking approval of Anaphylm™ (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000005/aqst-20260130.htm)) |
| September 17, 2026 | [Anaphylm™ (dibutepinephrine) NDA/BLA submission](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | completed | "On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/aqst-20260914.htm)) |
| March 16, 2027 | [Anaphylm™ (dibutepinephrine) PDUFA date](https://sec-api.dev/pdufa/dibutepinephrine) | AQST | Type I allergic reactions | scheduled | "Anaphylm Regulatory Milestones 18 Q1 2027Q4 2026Q3 2026Q2 2026Q1 2026 NDA Resubmitted Targeted Ex-U.S. filing in Canada PDUFA Goal Date March 16, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000077/corporatepowerpointprese.htm)) |

## Drugs

- [Anaphylm™ (dibutepinephrine)](https://sec-api.dev/pdufa/dibutepinephrine) (AQST)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-i-allergic-reactions.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Type I allergic reactions FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-i-allergic-reactions

```bibtex
@misc{secapidev_indications_type_i_allergic_reactions_20261116,
  title        = {Type I allergic reactions FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-i-allergic-reactions}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_i_allergic_reactions_20261116","title":"Type I allergic reactions FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-i-allergic-reactions","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
